These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8637241)

  • 21. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia.
    Jurcic JG; DeBlasio T; Dumont L; Yao TJ; Scheinberg DA
    Clin Cancer Res; 2000 Feb; 6(2):372-80. PubMed ID: 10690513
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drug-resistant AML cells and primary AML specimens are killed by 111In-anti-CD33 monoclonal antibodies modified with nuclear localizing peptide sequences.
    Kersemans V; Cornelissen B; Minden MD; Brandwein J; Reilly RM
    J Nucl Med; 2008 Sep; 49(9):1546-54. PubMed ID: 18703602
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies.
    Caron PC; Co MS; Bull MK; Avdalovic NM; Queen C; Scheinberg DA
    Cancer Res; 1992 Dec; 52(24):6761-7. PubMed ID: 1458463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells.
    Vitale C; Romagnani C; Puccetti A; Olive D; Costello R; Chiossone L; Pitto A; Bacigalupo A; Moretta L; Mingari MC
    Proc Natl Acad Sci U S A; 2001 May; 98(10):5764-9. PubMed ID: 11320212
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate.
    Bernstein ID
    Leukemia; 2000 Mar; 14(3):474-5. PubMed ID: 10720144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recombinant immunotoxins directed against the c-erb-2/HER2/neu oncogene product: in vitro cytotoxicity, pharmacokinetics, and in vivo efficacy studies in xenograft models.
    Rosenblum MG; Shawver LK; Marks JW; Brink J; Cheung L; Langton-Webster B
    Clin Cancer Res; 1999 Apr; 5(4):865-74. PubMed ID: 10213223
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin.
    Rosenblum MG; Marks JW; Cheung LH
    Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias.
    Burke JM; Caron PC; Papadopoulos EB; Divgi CR; Sgouros G; Panageas KS; Finn RD; Larson SM; O'Reilly RJ; Scheinberg DA; Jurcic JG
    Bone Marrow Transplant; 2003 Sep; 32(6):549-56. PubMed ID: 12953125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cell surface receptor-targeted therapy of acute myeloid leukemia: a review.
    Frankel AE; Sievers EL; Scheinberg DA
    Cancer Biother Radiopharm; 2000 Oct; 15(5):459-76. PubMed ID: 11155818
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo.
    Golay J; Di Gaetano N; Amico D; Cittera E; Barbui AM; Giavazzi R; Biondi A; Rambaldi A; Introna M
    Br J Haematol; 2005 Feb; 128(3):310-7. PubMed ID: 15667532
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker.
    Hamann PR; Hinman LM; Beyer CF; Lindh D; Upeslacis J; Flowers DA; Bernstein I
    Bioconjug Chem; 2002; 13(1):40-6. PubMed ID: 11792177
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and characterization of novel, recombinant immunotoxins targeting the Her2/neu oncogene product: in vitro and in vivo studies.
    Cao Y; Marks JD; Marks JW; Cheung LH; Kim S; Rosenblum MG
    Cancer Res; 2009 Dec; 69(23):8987-95. PubMed ID: 19934334
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monocyte-mediated lysis of acute myeloid leukemia cells in the presence of the bispecific antibody 251 x 22 (anti-CD33 x anti-CD64).
    Chen J; Zhou JH; Ball ED
    Clin Cancer Res; 1995 Nov; 1(11):1319-25. PubMed ID: 9815927
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase III trial of a humanized anti-CD33 antibody (HuM195) in patients with relapsed or refractory acute myeloid leukemia.
    Gibson AD
    Clin Lymphoma; 2002 Jun; 3(1):18-9. PubMed ID: 12141950
    [No Abstract]   [Full Text] [Related]  

  • 35. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo.
    Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F
    J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chimeric and humanized antibodies with specificity for the CD33 antigen.
    Co MS; Avdalovic NM; Caron PC; Avdalovic MV; Scheinberg DA; Queen C
    J Immunol; 1992 Feb; 148(4):1149-54. PubMed ID: 1737932
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis.
    Martínez-Torrecuadrada JL; Cheung LH; López-Serra P; Barderas R; Cañamero M; Ferreiro S; Rosenblum MG; Casal JI
    Mol Cancer Ther; 2008 Apr; 7(4):862-73. PubMed ID: 18413799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Internalization and cell cycle-dependent killing of leukemic cells by Gemtuzumab Ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity.
    Jedema I; Barge RM; van der Velden VH; Nijmeijer BA; van Dongen JJ; Willemze R; Falkenburg JH
    Leukemia; 2004 Feb; 18(2):316-25. PubMed ID: 14614514
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A CD33-specific single-chain immunotoxin mediates potent apoptosis of cultured human myeloid leukaemia cells.
    Schwemmlein M; Peipp M; Barbin K; Saul D; Stockmeyer B; Repp R; Birkmann J; Oduncu F; Emmerich B; Fey GH
    Br J Haematol; 2006 Apr; 133(2):141-51. PubMed ID: 16611304
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude mouse models in the antitumor efficacy of monoclonal antibody.
    Kawata A; Yoshida M; Okazaki M; Yokota S; Barcos M; Seon BK
    Cancer Res; 1994 May; 54(10):2688-94. PubMed ID: 8168098
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.